Compare Stocks: ACHL, NMRA, SIGA, and ANTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ANTX Anthem	$5.36 -1.8%	$5.44	$1.00 ▼ $7.19	$206.04M	-0.99	202,620 shs	156,796 shs
NMRA Neumora Therapeutics	$0.83 -16.8%	$1.51	$0.83 ▼ $3.65	$187.78M	2.71	694,723 shs	1.40 million shs
SIGA Siga Technologies	$2.98 -5.4%	$3.19	$2.83 ▼ $9.45	$226.33M	0.97	690,244 shs	478,590 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANTX Anthem	-1.83%	-10.37%	-10.52%	+9.39%	+332.26%
NMRA Neumora Therapeutics	-16.82%	-33.50%	-48.04%	-45.67%	-45.31%
SIGA Siga Technologies	-5.40%	-6.88%	-0.67%	-30.86%	-66.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ANTX Anthem	$5.36 -1.8%	$5.44	$1.00 ▼ $7.19	$206.04M	-0.99	202,620 shs	156,796 shs
NMRA Neumora Therapeutics	$0.83 -16.8%	$1.51	$0.83 ▼ $3.65	$187.78M	2.71	694,723 shs	1.40 million shs
SIGA Siga Technologies	$2.98 -5.4%	$3.19	$2.83 ▼ $9.45	$226.33M	0.97	690,244 shs	478,590 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANTX Anthem	-1.83%	-10.37%	-10.52%	+9.39%	+332.26%
NMRA Neumora Therapeutics	-16.82%	-33.50%	-48.04%	-45.67%	-45.31%
SIGA Siga Technologies	-5.40%	-6.88%	-0.67%	-30.86%	-66.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ANTX Anthem	2.33	Hold	$9.00	67.91% Upside
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	690.50% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACHL, NMRA, SIGA, and ANTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	ANTX Anthem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/17/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	NMRA Neumora Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
7/6/2026	ANTX Anthem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/18/2026	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$6.00 ➝ $4.00
6/16/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $7.00
6/16/2026	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $5.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
SIGA Siga Technologies	$94.57M	2.26	$0.32 per share	9.46	$2.78 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	N/A
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)

Latest ACHL, NMRA, SIGA, and ANTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ANTX Anthem	N/A	14.32	14.32
NMRA Neumora Therapeutics	1.19	4.50	4.50
SIGA Siga Technologies	N/A	21.72	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ANTX Anthem	90.47%
NMRA Neumora Therapeutics	47.65%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ANTX Anthem	22.61%
NMRA Neumora Therapeutics	26.94%
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable

ACHL, NMRA, SIGA, and ANTX Headlines

Recent News About These Companies

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor einem Jahr verloren

September 8, 2026 | finanzen.netF

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

September 6, 2026 | insidermonkey.com

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

September 4, 2026 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Shares Up 2.6% - Should You Buy?

August 31, 2026 | marketbeat.com

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor 10 Jahren verdient

August 31, 2026 | finanzen.netF

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

SIGA Technologies 2026年第二季度每股收益$0.17，盘后股价小幅上涨

August 6, 2026 | cn.investing.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

August 6, 2026 | markets.businessinsider.com

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026 | globenewswire.com

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

July 28, 2026 | seekingalpha.com

Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?

June 30, 2026 | finance.yahoo.com

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

May 22, 2026 | finance.yahoo.com

SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed

May 15, 2026 | finance.yahoo.com

Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings

May 14, 2026 | finance.yahoo.com

SIGA (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | fool.com

SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months

May 8, 2026 | msn.com

SIGA Technologies, Inc. Q1 2026 Earnings Call Summary

May 8, 2026 | finance.yahoo.com

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026 | globenewswire.com

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

April 30, 2026 | globenewswire.com

Why SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%

March 28, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, NMRA, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Anthem NASDAQ:ANTX

$5.36 -0.10 (-1.83%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$5.35 -0.01 (-0.19%)

As of 09/15/2026 07:30 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Neumora Therapeutics NASDAQ:NMRA

$0.83 -0.17 (-16.82%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$0.85 +0.02 (+2.37%)

As of 04:00 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Siga Technologies NASDAQ:SIGA

$2.98 -0.17 (-5.40%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.97 -0.01 (-0.37%)

As of 09/15/2026 07:30 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHL, NMRA, SIGA, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHL, NMRA, SIGA, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHL, NMRA, SIGA, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, NMRA, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Anthem NASDAQ:ANTX

Neumora Therapeutics NASDAQ:NMRA

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHL, NMRA, SIGA, and ANTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHL, NMRA, SIGA, and ANTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHL, NMRA, SIGA, and ANTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, NMRA, SIGA, and ANTX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Anthem NASDAQ:ANTX

Neumora Therapeutics NASDAQ:NMRA

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools